These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 28710508)

  • 21. Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?
    Wang S; Yang Z; Wang Z
    Oncotarget; 2015 Jul; 6(20):18206-23. PubMed ID: 26156021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
    Funakoshi T; Latif A; Galsky MD
    Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non-small-cell lung cancer: A PRISMA-compliant meta-analysis.
    Lv WW; Zhang JJ; Zhou XL; Song Z; Wei CM
    Medicine (Baltimore); 2019 Jun; 98(23):e15806. PubMed ID: 31169681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.
    Qi WX; Shen Z; Tang LN; Yao Y
    Br J Clin Pharmacol; 2014 Oct; 78(4):748-62. PubMed ID: 24661224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
    Santoni M; Conti A; De Giorgi U; Iacovelli R; Pantano F; Burattini L; Muzzonigro G; Berardi R; Santini D; Cascinu S
    Int J Cancer; 2014 Aug; 135(4):763-73. PubMed ID: 24127298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis.
    Zhang ZF; Wang T; Liu LH; Guo HQ
    PLoS One; 2014; 9(3):e90135. PubMed ID: 24621598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis.
    Sivendran S; Liu Z; Portas LJ; Yu M; Hahn N; Sonpavde G; Oh WK; Galsky MD
    Cancer Treat Rev; 2012 Nov; 38(7):919-25. PubMed ID: 22651902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis.
    Qi WX; Min DL; Shen Z; Sun YJ; Lin F; Tang LN; He AN; Yao Y
    Int J Cancer; 2013 Jun; 132(12):2967-74. PubMed ID: 23225494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diarrhea with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: A meta-analysis of randomized controlled trials.
    Li J; Gu J
    Crit Rev Oncol Hematol; 2019 Feb; 134():31-38. PubMed ID: 30771871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients.
    Ding F; Liu B; Wang Y
    J Am Acad Dermatol; 2020 Sep; 83(3):788-796. PubMed ID: 30991119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of vascular epithelial growth factor receptor-tyrosine kinase inhibitors in the treatment of advanced breast cancer: a meta-analysis of 12 randomized controlled trials.
    Li J; Huang S; Zheng W; Ding H; Zhang Y; Huang S; Zhang Z; Chen B; Liang Z; He G; Xiao X; Li S; Xu T; Chen X
    Curr Med Res Opin; 2013 Dec; 29(12):1691-9. PubMed ID: 23981081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis.
    Roy B; Das A; Ashish K; Bandyopadhyay D; Maiti A; Chakraborty S; Stone ME; Philpotts LL; Nowak RJ; Patwa HS
    Neurology; 2019 Jul; 93(2):e143-e148. PubMed ID: 31167931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of Gastrointestinal Events During Vandetanib Therapy in Patients With Cancer: A Systematic Review and Meta-analysis of Clinical Trials.
    Yang X; Pan X; Cheng X; Kuang Y; Cheng Y
    Am J Ther; 2017 May; 24(3):e351-e360. PubMed ID: 26280290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and risk of hypertension associated with cabozantinib in cancer patients: a systematic review and meta-analysis.
    Zhang X; Shao Y; Wang K
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1109-15. PubMed ID: 27181268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis.
    Chen YC; Chen JH; Hsieh FI
    J Chin Med Assoc; 2024 Jan; 87(1):48-57. PubMed ID: 37991373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.
    Abdel-Rahman O; ElHalawani H; Ahmed H; Ellithy M
    Expert Rev Gastroenterol Hepatol; 2015; 9(11):1433-45. PubMed ID: 26365425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastrointestinal events with PARP inhibitors in cancer patients: A meta-analysis of phase II/III randomized controlled trials.
    Sun W; Li J; Zhang Z; Su X
    J Clin Pharm Ther; 2021 Apr; 46(2):241-255. PubMed ID: 33135237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors.
    Yuan A; Kurtz SL; Barysauskas CM; Pilotte AP; Wagner AJ; Treister NS
    Oral Oncol; 2015 Nov; 51(11):1026-1033. PubMed ID: 26403941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Skin Toxicities with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials.
    Sun W; Li J
    Cancer Invest; 2019; 37(6):253-264. PubMed ID: 31303065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?
    Furuya-Kanamori L; Doi SA; Onitilo A; Akhtar S
    Expert Opin Drug Saf; 2020 Feb; 19(2):223-228. PubMed ID: 31698959
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.